News

Filter News By

Clear Filters

  1. ICER Announces Assessment of Triple-Combination Therapy

    September 13, 2019

    The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The first opportunity to comment runs through Sept. 25.

    Topics:

  2. The CF Foundation Awards Arcturus Therapeutics Up to $15M for RNA Therapy

    August 5, 2019

    The Cystic Fibrosis Foundation has increased its award to Arcturus Therapeutics to up to $15 million to develop a mutation-agnostic therapy for people with cystic fibrosis.

  3. Merrill/Bank of America Raises More Than $32,000 Through Matching Gifts

    July 26, 2019

    To support a pair of colleagues’ adoption of a baby boy, Christian, Merrill/Bank of America has raised more than $32,000 through their matching gifts program.

    Topics:

  4. CF Foundation Announces 2019 Impact Grant Recipients

    July 23, 2019

    Recipients include five innovative programs from around the country that empower the CF community.

  5. Application for Triple-Combination Therapy Submitted to the FDA

    July 22, 2019

    Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.

  6. Rep. Mark Amodei Announced as New Co-Chair of Congressional CF Caucus

    July 12, 2019

    U.S. Rep. Mark Amodei of Nevada will join fellow Rep. Jim McGovern and Sens. Chuck Grassley and Ed Markey in co-chairing the Congressional Cystic Fibrosis Caucus, championing awareness of the rare disease and the Cystic Fibrosis Foundation’s search for a cure.

    Topics:

More Posts View All Posts

Follow Us On